Skip to search formSkip to main contentSkip to account menu

Duligotuzumab

Known as: DULIGOTUMAB 
An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

MEHD7945A
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab)
Tumor resistance to treatment paved the way toward the development of single agent drugs that target multiple molecular… 
2018
2018
PO-519 Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified colorectal cancer models
Introduction Cetuximab and panitumumab, antibodies directed against the epidermal growth factor receptor (EGFR), are an effective… 
2017
2017
Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Commentary: randomized Phase II Study of Duligotuzumab (meHD7945a) vs. Cetuximab in Squamous Cell Carcinoma of the Head and neck… 
2017
2017
Combination of duligotuzumab, anti HER3 antibody or taselisib, PI3K INhibitor with trastuzumab shows synergetic antitumoral activity in HER2 positive gastric cancer cells.
Highly Cited
2016
Highly Cited
2016
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Background Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor… 
2015
2015
Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
Background: Duligotuzumab (MEHD, MEHD7945A) is a novel dual-action humanized IgG1 antibody that blocks EGFR and HER3 binding… 
2015
2015
Duligotuzumab. Human anti-EGFR/anti-HER3 MAb, colorectal cancer therapy, head and neck cancer therapy
2015
2015
Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
2014
2014
Phase 1b Study of MEHD7945A (DULIGOTUZUMAB) Plus Cisplatin/Fluorouracil or Carboplatin/Paclitaxel for First-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
P.M. Clement,1 J-P. Machiels,2 L. Wirth,3 P. Specenier,4 T. Seiwert,5 F. Mardjuadi,2 X. Wang,7 A. Kapp,7 S. Royer-Joo,7 E. Penuel… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)